Inventiva S.A. (IVA) Presents at 44th Annual J.P.

Company Overview - Inventiva has undergone a significant transformation in the last 18 months, indicating a strategic shift or development within the organization [4] - The company is currently conducting a fully enrolled Phase III trial for its lead asset, lanifibranor, which is positioned as a potential best-in-class oral therapy for MASH [4] Clinical Development - The Phase III trial design is based on a successful Phase IIb trial involving over 200 patients, which was published in the New England Journal of Medicine with positive results [4] - The readout for the Phase III trial is anticipated in the second half of this year, suggesting a critical upcoming milestone for the company [4] Financial Position - The company has received a substantial amount of funding, which may support its ongoing clinical trials and operational activities [5]